Boston Scientific Corporation Q1 2026 Earnings Call Summary
Boston Scientific Corporation revised its full-year organic growth guidance downward to 6.5%-8% due to challenges in several business units, including WATCHMAN, EP, and Urology. The company reported operating margins of 28.8% in Q1 and expects full-year adjusted EPS of $3.34-$3.41. The second quarter is anticipated to be the most challenging in 2026 due to difficult year-over-year comparisons.
Topics: Acquisition Earnings Guidance Market Performance Organizational Efficiency Product Launch